All In Biotech

Drug Trial Radar · NCT02589782

Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)

A Randomised, Controlled, Open-Label, Phase II-III Trial to Evaluate the Safety and Efficacy of Regimens Containing Bedaquiline and Pretomanid for the Treatment of Adult Patients With Pulmonary Multidrug Resistant Tuberculosis

Last checked: Nov 19, 2026Latest source record: May 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 552 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

552

Actual

Start

Jan 2017

Primary completion

Aug 5, 2022

Study completion Aug 5, 2022

Sponsor

Lead sponsor
Medecins Sans Frontieres, NetherlandsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
London School of Hygiene and Tropical Medicine; Global Alliance for TB Drug Development; University College, London; Drugs for Neglected Diseases; Swiss Tropical & Public Health Institute; eResearch Technology, Inc.; Ministry of Health, Republic of Uzbekistan; World Health Organization; Ministry of Public Health, Republic of Belarus; THINK TB & HIV Investigative Network; University of Liverpool; Wits Health Consortium (Pty) Ltd; Rutgers, The State University of New Jersey; University of California, San Francisco
First posted
Oct 28, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TB PRACTECAL is a multi-centre, open label, multi-arm, randomised, controlled, phase II-III trial; evaluating short treatment regimens containing bedaquiline and pretomanid in combination with existing and re-purposed anti-TB drugs for the treatment of biologically confirmed pulmonary multi drug-resistant TB (MDR-TB).

Conditions

  • Tuberculosis, Multidrug-Resistant
  • Extensively Drug-Resistant Tuberculosis
  • Tuberculosis, Pulmonary

Interventions

  • BedaquilineDrug

  • PretomanidDrug

  • MoxifloxacinDrug

  • LinezolidDrug

  • ClofazimineDrug

  • Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1:Percentage of patients with culture conversion in liquid media at 8 weeks post randomisation.Time frame: 8 weeks post randomisation
  2. Stage 1: Percentage of patients who discontinue treatment for any reason or dieTime frame: 8 weeks post randomisation
  3. Stage 2: Percentage of patients with an unfavourable outcome (failure, death, recurrence, loss to follow-up)Time frame: 72 weeks post-randomisation

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital

    Minsk, Belarus

  • Helen Jospeh Hospital

    Johannesburg, Gauteng, South Africa

  • THINK Clinical Trial Unit, Hillcrest

    Durban, KwaZulu-Natal, South Africa

  • King DinuZulu Hospital

    Durban, KwaZulu-Natal, South Africa

  • Doris Goodwin Hospital

    Pietermaritzburg, KwaZulu-Natal, South Africa

  • Sh Alimov Republican Specialised Scientific-Practical Medical Centre for Phthysiology and Pulmonology Hospital

    Tashkent, Uzbekistan

  • Republican TB Hospital No. 2

    Nukus, Karakalpakstan, Uzbekistan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.